Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Newling

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
European Urology|July 21, 2001
The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion studyD W Newling, J Hetherington, S K Sundaram, et al.
Cancer|September 1, 1990
EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatmentM R Robinson, L Denis, D W Newling, et al.
BJU International|June 8, 2004
The 24-h frequency-volume chart in adults reporting no voiding complaints: defining reference values and analysing variablesE P van Haarst, E A Heldeweg, D W Newling, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cellsA A Geldof, M A De Kleijn, B R Rao, et al.
Urology|May 1, 1994
Ultrasound in squamous cell carcinoma of the penis; a useful addition to clinical staging? A comparison of ultrasound with histopathologyS Horenblas, R Kröger, M P Gallee, et al.
British Journal of Urology|December 1, 1983
Low-dose doxorubicin in the management of advanced carcinoma of the prostateM R Robinson, S Chandrysekran, D W Newling, et al.
European Urology|January 1, 1990
A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumourJ A Cumming, D Kirk, D W Newling, et al.
Urology|May 1, 1997
Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat modelA A Geldof, P L van den Tillaar, D W Newling, et al.
European Urology|January 1, 1986
An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostateJ K Siddall, E H Cooper, D W Newling, et al.
British Journal of Urology|December 1, 1985
Mitomycin C in superficial bladder cancer: 24-month follow-upJ J Somerville, D W Newling, B Richards, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
European Urology|July 21, 2001
The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion studyD W Newling, J Hetherington, S K Sundaram, et al.
Cancer|September 1, 1990
EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatmentM R Robinson, L Denis, D W Newling, et al.
BJU International|June 8, 2004
The 24-h frequency-volume chart in adults reporting no voiding complaints: defining reference values and analysing variablesE P van Haarst, E A Heldeweg, D W Newling, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cellsA A Geldof, M A De Kleijn, B R Rao, et al.
Urology|May 1, 1994
Ultrasound in squamous cell carcinoma of the penis; a useful addition to clinical staging? A comparison of ultrasound with histopathologyS Horenblas, R Kröger, M P Gallee, et al.
British Journal of Urology|December 1, 1983
Low-dose doxorubicin in the management of advanced carcinoma of the prostateM R Robinson, S Chandrysekran, D W Newling, et al.
European Urology|January 1, 1990
A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumourJ A Cumming, D Kirk, D W Newling, et al.
Urology|May 1, 1997
Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat modelA A Geldof, P L van den Tillaar, D W Newling, et al.
European Urology|January 1, 1986
An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostateJ K Siddall, E H Cooper, D W Newling, et al.
British Journal of Urology|December 1, 1985
Mitomycin C in superficial bladder cancer: 24-month follow-upJ J Somerville, D W Newling, B Richards, et al.
Pageof 11